From the microenvironment to the CLL patient
MRD assessment: NGS vs. flow cytometry
A Pharmacist's view on biosimilars
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Trials of BiTEs for the treatment of acute leukemias